Press Releases for MYGN

Press Releases
Myriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results
EpiCept Corporation Reports Third Quarter Results,Provides Business Update
Myriad Genetics Reports First Quarter Fiscal 2010 Financial Results; Revenue Grows 22%; Net Income Rises 111% Compared to Prior Year
Nasdaq Panel Grants EpiCept's Request for Continued Listing
Myriad Genetics Elects Louise Phanstiel and Lawrence Best to Its Board of Directors
Myriad Genetics Reports Fiscal 2009 Financial Results; Net Income Rises 77%, Product Revenue Up 47%
Myriad Genetics Reports Fiscal 2009 Financial Results
EpiCept Corporation Reports Second Quarter 2009 Operating and Financial Results, Provides Business Update
Myriad Genetics to Report Fiscal 2009 Fourth Quarter and Year-End Financial Results On August 25
PDI Appoints Gerald P. Belle As Lead Independent Director
NASDAQ OMX Announces Second Quarter 2009 New Listings Statistics
Myriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business
Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year
EpiCept Shares on the OMX Nordic Exchange Transferred Back to Ordinary Position From Observation Segment
EpiCept Announces Pricing of Public Offering
Myriad Genetics Announces Effectiveness of Myriad Pharmaceuticals Registration Statement on Form 10
Myriad Genetics Sets Record and Distribution Dates for Spin-Off of Myriad Pharmaceuticals
EpiCept Announces Webcast of Annual Meeting of Stockholders
Myriad Genetics to Present at The Goldman Sachs 30th Annual Global Healthcare Conference and The 8th Annual Needham Life Sciences Conference
ACLU sues over cancer gene patents
ACLU sues over cancer gene patents
EpiCept Corporation Reports First Quarter 2009 Operating and Financial Results
Stock News for Tuesday, May 5, 2009: MCIO Significant Potential
Myriad Genetics Reports Fiscal 2009 Third Quarter Financial Results
EpiCept to Report First Quarter 2009 Operating and Financial Results on May 7, 2009
New Study Published in CANCER Supports Use of BRACAnalysis Testing Across Broad Ethnic Populations
Notice of the Annual Meeting of Stockholders of EpiCept Corporation - Apr 30 2009 12:55AM
Myriad Genetics to Present at Bank of America and Merrill Lynch 2009 Health Care Conference and the Eighth Annual JMP Securities Research Conference
Myriad Genetics Launches OnDose, Its Seventh Molecular Diagnostic Product
Myriad Genetics to Report Fiscal 2009 Third Quarter Financial Results on May 4
Myriad Pharmaceuticals Receives IND Approval for New Cancer Drug
AnalystChoice.Com Free CFA Opinion on KCI, FAST, MYGN and ONXX
Zacks Analyst Blog Highlights: PepsiCo, Dr. Pepper Snapple Group, Auxilium Pharmaceuticals, Myriad Genetics and Autoliv, Inc. - Mar 27 2009 7:00AM
Myriad Applauds New ACOG Guidelines for Hereditary Breast and Ovarian Cancer
Myriad Genetics to Present at Citi's 4th Annual Biotech Day on April 1, 2009
Myriad Genetics to Present at Cowen Health Care Conference on March 17, 2009
Myriad Genetics Announces 2-for-1 Stock Split
Zacks Industry Rank Analysis Highlights: Archer Daniels Midland Company, Broadcom, Dean Foods, Liberty Property Trust and Myriad Genetics
Zacks Analyst Blog Highlights: Costco, Myriad Genetics, Huntington Bancshares, School Specialty, Inc. And Telefonica
Myriad Genetics, Inc. Reports Results for Second Quarter of Fiscal 2009
Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat
Myriad Genetics Announces Second Quarter Fiscal 2009 Financial Results Conference Call
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
BenchmarkJournal.Com (Complimentary) Analyst Review for and ROST, HERO, FDRY and MYGN
Myriad Genetics, Inc. Receives Approval From New York Stock Exchange to Proceed With New Listing
Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2009
Myriad Genetics Announces First Quarter Fiscal 2009 Financial Results Conference Call
Myriad Genetics Announces Plan to Separate Into Two Independent Public Companies
Myriad Genetics Acquires Novel Therapeutic Drug Management Technology From Saladax Biomedical
MultiVu Video Feed: WOMEN WITH A HEREDITARY RISK OF BREAST AND OVARIAN CANCER ARE ENCOURAGED TO GET TESTED - THOSE WITH AN ALTERED BRCA1 OR BRCA2 GENE HAVE A 56 TO 87 PERCENT RISK TO DEVELOP BREAST CANCER BY AGE 70
Myriad Genetics Announces Topline Results of Phase 1 Trial of Vivecon for HIV
Semi-annual Changes to the NASDAQ Q-50 Index - Sep 15 2008 7:12AM
Myriad Genetics Board Explores Prospect of Separating Diagnostic and Pharmaceutical Businesses
Myriad Genetics Reports Financial Results for Fiscal 2008
Myriad Genetics Announces Fourth Quarter and Year-End Fiscal 2008 Financial Results Conference Call
Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan(TM) in Alzheimer's Disease
Myriad Genetics' Alzheimer's Disease Drug Mechanism of Action Detailed in Nature Article
Myriad Genetics Selects Lundbeck as European Partner for Flurizan - May 27 2008 1:01AM
Myriad Genetics Reports Results for Third Quarter of Fiscal 2008 - Jun 2 2008 1:37AM
Myriad Genetics Announces Third Quarter Fiscal 2008 Financial Results Conference Call